4 Healthcare Stock Stories Ready for a Midweek Investment Checkup
Merck & Co. (NYSE:MRK): Closing price $48.11
A study presented Wednesday at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy in Denver indicated that too few American adults have been vaccinated for shingles, which is a painful condition similar to chicken pox. Research calls for efforts to increase the inoculation that is recommended by the United States government.
Fewer than 2 in 10 Americans aged 60 and older have been vaccinated, and nearly one-third of Americans will get shingles in their lifetime, with some 1 million cases in the U.S. annually, according to the Centers for Disease Control and Prevention. The vaccine Zostavax, made by Merck & Co., was approved for sale in 2006 for people 60 and older, and for use by those in their 50s in 2011.